References
- Subedi M, Bajaj S, Kumar MS, Yc M. An overview of tramadol and its usage in pain management and future perspective. Biomed Pharmacother 2019; 111: 443-51. doi: 10.1016/j.biopha.2018.12.085
- Besic N, Smrekar J, Strazisar B. Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study. Breast Cancer Res Treat 2020; 182: 655-63. doi: 10.1007/s10549-020-05713-3
- World Health Organisation. Tramadol, update review report. [Internet]. 2014. p. 1-39. [cited 2022 Aug 14]. Available at:
http://www.who.int/medicines/areas/quality_safety/6_1_Update.pdf - Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav 2014; 123: 25-33. doi: 10.1016/j.pbb.2013.10.018
- Wang S. Historical review: opiate addiction and opioid receptors. Cell Transplant 2019; 28: 233-8. doi: 10.1177/0963689718811060
- Yoshida K, Nishizawa D, Ide S, Ichinohe T, Fukuda KI, Ikeda K. A pharmacogenetics approach to pain management. Neuropsychopharmacol Rep 2018; 38: 2-8. doi: 10.1002/npr2.12003
- Muriel J, Margarit C, Barrachina J, Ballester P, Flor A, Morales D, et al. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic Clin Pharmacol Toxicol 2019; 124: 439-48. doi: 10.1111/bcpt.13155
- Liu YC, Wang WS. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer 2012; 118: 1718-25. doi: 10.1002/cncr.26430
- Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559-66. doi: 10.1038/sj.clpt.6100385
- Lötsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009; 19: 429-36. doi: 10.1097/fpc.0b013e32832b89da
- Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48: 1232-9. doi: 10.1111/j.1399-6576.2004.00517.x
- De Gregori M, Diatchenko L, Ingelmo PM, Napolioni V, Klepstad P, Belfer I, et al. Human genetic variability contributes to postoperative morphine consumption. J Pain 2016; 17: 628-36. doi: 10.1016/j.jpain.2016.02.003
- Riffo-Campos ÁL, Riquelme I, Brebi-Mieville P. Tools for sequence-based miRNA target prediction: what to choose? Int J Mol Sci 2016; 17: 1987. doi: 10.3390/ijms17121987
- Xu W, San Lucas A, Wang Z, Liu Y. Identifying microRNA targets in different gene regions. BMC Bioinformatics 2014; 15: S4. doi: 10.1186/1471-2105-15-S7-S4
- Lu Z, Xu J, Xu M, Pasternak GW, Pan YX. Morphine regulates expression of μ-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the μ-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 2014; 85: 368-80. doi: 10.1124/mol.113.089292
- Zheng H, Law PY, Loh HH. Non-coding RNAs regulating morphine function: with emphasis on the in vivo and in vitro functions of miR-190. Front Genet 2012; 3: 113. doi: 10.3389/fgene.2012.00113
- Wu Q, Law PY, Wei LN, Loh HH. Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 3’ untranslated region: a role for micro-RNA23b. FASEB J 2008; 22: 4085-95. doi: 10.1096/fj.08-108175
- Rodríguez RE. Morphine and microRNA activity: is there a relation with addiction? Front Genet 2012; 3: 223. doi: 10.3389/fgene.2012.00223
- Besic N, Smrekar J, Strazisar B. Acute pain and side effects after tramadol in breast cancer patients: results of a prospective double-blind randomized study. Sci Rep 2020; 10: 18766. doi: 10.1038/s41598-020-75961-2
- Fitz-Henry J. The ASA classification and peri-operative risk. Ann R Coll Surg Engl 2011; 93: 185-7. doi: 10.1308/rcsann.2011.93.3.185a
- Cariaso M, Lennon G. SNPedia: a wiki supporting personal genome annotation, interpretation and analysis. Nucleic Acids Res 2012; 40: D1308-12. doi: 10.1093/nar/gkr798
- Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015; 31: 3555-7. doi: 10.1093/bioinformatics/btv402
- Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database. Nucleic Acids Research 2020; 48: D148-54. doi: 10.1093/nar/gkz896
- Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Research 2020; 48: D127-31, doi: 10.1093/nar/gkz757
- Chang L, Zhou G, Soufan O, Xia J. miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Research 2020; 48: W244-51. 10.1093/nar/gkaa467
- Hwang IC, Park JY, Myung SK, Ahn HY, Fukuda K, Liao Q. OPRM1 A118G gene variant and postoperative opioid requirement: a systematic review and meta-analysis. Anesthesiology 2014; 121: 825-34. doi: 10.1097/ALN.0000000000000405
- National Library of Medicine (US), National Center for Biotechnology Information. db SNP: rs1799971. [cited 2022 Oct 30]. Available at:
https://www.ncbi.nlm.nih.gov/snp/rs1799971 - Matic M, de Hoogd S, de Wildt SN, Tibboel D, Knibbe CA, van Schaik RH. OPRM1 and COMT polymorphisms: implications on postoperative acute, chronic and experimental pain after cardiac surgery. Pharmacogenomics 2020; 21: 181-93. doi: 10.2217/pgs-2019-0141
- Muriel J, Margarit C, Planelles B, Serralta MJ, Puga C, Inda MD, et al. OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients. Ann N Y Acad Sci 2018; 1425: 82-93. doi: 10.1111/nyas.13735
- The Pharmacogenomics Knowledge Base (PharmGKB). Variant annotations: rs1799971. [cited 2022 Oct 30]. Avalable at:
https://www.pharmgkb.org/variant/PA166156991/variantAnnotation - Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103: 77-87. doi: 10.1111/j.1471-4159.2007.04738.x
- National Library of Medicine (US), National Center for Biotechnology Information. db SNP: rs677830. [cited 2022 Oct 30]. Available at:
https://www.ncbi.nlm.nih.gov/snp/rs677830 - Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ 2016; 188: E352-61. doi: 10.1503/cmaj.151276
- Wu Q, Zhang L, Law PY, Na Wei LN, Loh HH. Long-term morphine treatment decreases the association of μ-opioid receptor (MOR1) mRNA with polysomes through miRNA23b. Mol Pharmacol 2009; 75: 744-50. doi: 10.1124/mol.108.053462
- Wang S, Lv C, Jin H, Xu M, Kang M, Chu H, et al. A common genetic variation in the promoter of miR-107 is associated with gastric adenocarcinoma susceptibility and survival. Mutat Res 2014; 769: 35-41. doi: 10.1016/j. mrfmmm.2014.07.002
- Im YB, Jee MK, Choi JI, Cho HT, Kwon OH, Kang SK. Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord. Cell Death Dis 2012; 3: e426. doi: 10.1038/cddis.2012.168
- Favereaux A, Thoumine O, Bouali-Benazzouz R, Roques V, Papon MA, Salam SA, et al. Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR-103: role in pain. EMBO J 2011; 3018: 3830-41. doi: 10.1038/emboj.2011.249
- Stamer UM, Zhang L, Stüber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics 2010; 11: 843-64. doi: 10.2217/pgs.10.47